Marker Therapeutics, Inc.

Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.

MRKR | NDAQ

Overview

Corporate Details

ISIN(s):: US57055L1070 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://markertherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation, non-genetically modified T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology, Multi-Antigen Recognizing (MAR) T cells, expands a patient's natural T cells to recognize and eliminate tumors expressing multiple antigens. This approach aims to provide durable anti-tumor responses with a favorable safety profile compared to genetically engineered cell therapies. The technology was developed at Baylor College of Medicine. Its lead product candidate, MT-601, is being evaluated in a Phase 1 study for lymphoma patients who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Marker Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marker Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Marker Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
DaehanPharmaceutical Develops and manufactures pharmaceuticals and health foods for human and animal markets worldwide.	South Korea	023910
Daesung Microbiological Labs. Co. Ltd Researches and manufactures veterinary vaccines and medicines for livestock, fish, and canines.	South Korea	036480
DAEWOONG PHARMA A global R&D partner for drug development, manufacturing, and commercialization services.	South Korea	069620
DAIICHI SANKYO COMPANY, LIMITED A global pharmaceutical firm developing novel therapies with a focus on oncology and ADCs.	Japan	4568
Daito Pharmaceutical Co., Ltd. Manufactures APIs, generic drugs, and health foods; provides contract manufacturing services.	Japan	4577
Dare Bioscience, Inc. Advancing innovative therapies for women's health in contraception, fertility, and sexual health.	United States of America	DARE
Day One Biopharmaceuticals, Inc. Developing targeted cancer therapies for all ages, with a focus on pediatric oncology.	United States of America	DAWN
DBV Technologies S.A. Developing non-invasive skin patch immunotherapies for food allergies and immune diseases.	United States of America	DBVT
D&D Pharmatech Inc. Develops oral & injectable peptide therapies for metabolic & chronic diseases like obesity.	South Korea	347850
Dechra Pharmaceuticals PLC Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.	United Kingdom	DPH